Dr Reddy's Seeks Emergency Use Approval Of Sputnik-V Vaccine

Pharmaceutical MNC Dr Reddy’s have applied for emergency use authorization of Russian COVID-19 vaccine ‘Sputnik-V’ in India. Showing 91.6% efficacy in the last-stage trials, the vaccine maker has assured to submit the test interim data by February 21. Produced by Moscow’s Gamaleya Institute and registered in almost 30 countries, the vaccine will be the most effective in India if approved. Reportedly, Reddy’s and Russian Development Investment Fund collaborated to conduct clinical studies.